Infused PMN-MDSCs from G-CSF-mobilized PBSCs protect against II-IV° acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

BMC Immunol · 2026 · PMC12911113 · PMID 41572151

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

While a high dose of PMN-MDSCs (>8,000/μL) was associated with a strong trend towards lower relapse and significantly better 300-day leukemia-free survival (LFS) (Table 3 ), the most striking effect was observed for the LOX-1+ PMN-MDSC subset.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.